GlaxoSmithKline to pay $3 billion settlement for bribing doctors, hiding data from the FDA, and for lying about their products
That is a HUGE settlement. Huge.
The company pleaded guilty to three crimes and agreed to hand over $1 billion for how it marketed the antidepressants Wellbutrin and Paxil and for failing to report some data to the FDA for the diabetes drug Avandia.
The Justice Department said the company marketed Wellbutrin as a treatment for a variety of conditions it was never approved for, including sexual problems and drug addiction. It also said the company pushed Paxil as a treatment for people younger than 18 even though it was only approved for adults.
GlaxoSmithKline also agreed to pay another $2 billion to settle civil claims about its marketing, including kickbacks that went to doctors who prescribed the company’s drugs.